Abstracts tagged "B-Cell Targets"

Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad Rovin¹, Elsa Martins², Cary Austin³, Harini Raghu³, Caleb Chan³, Patrick Chang³, Jay Garg³, Valeria Alberton⁴, Mittermayer Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra Palazuelos⁷, Teresa Baczkowska⁸, José Alfaro⁹, Jorge Ravelo-Hernández¹⁰, Richard Furie¹¹, Luís Pinto¹², Eduardo Albiero¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler², Theodore Omachi³, William Pendergraft III³ and Ana Malvar¹⁶, ¹Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³Genentech, Inc., South San Francisco, California, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C., Mexico City, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clinica San Juan Bautista, Unidad de Investigacion en Reumatologia e Inmunologia, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, Great Neck, New York, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Medellín, Colombia, ¹³Sanatorio Allende, Córdoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, Arkansas, ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁶Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: 0994 • ACR Convergence 2025
UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Licui Jiang¹, Fengtao you¹, Kunmin Yan¹, Jianan Yao¹, Hai Wu¹, Jian Wu², Xin Chang², Cheng Peng², Huimin Meng¹, Min Wang³, Ping Zhang³, Bozhen Zhang⁴ and Lin Yang⁵, ¹PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China,, Suzhou, China (People's Republic), ²The First Affiliated Hospital of Soochow University, Suzhou, China (People's Republic), ³PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China,, Suzhou, China (People's Republic), ⁴PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China,, Suzhou, China (People's Republic), ⁵PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China; Cyrus Tang Medical Institute, Soochow University, Suzhou, Jiangsu, China, Suzhou, China (People's Republic)
Background/Purpose: Current therapies inadequately restore immune homeostasis due to incomplete pathogenic cell clearance and limited multi-lineage targeting. UTAA91 integrates: 1) PD-1 agonist-targeted cytotoxicity: The PD-1…
Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Chunli Mei¹, Xin Guan¹, Rong Du¹, Bin Wu², You Song¹, Xiaoqi Chen³, Mengjiao Li¹, Xiaojing Liu¹, Xi Cheng¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Di Wu¹, Guiqi Quan¹, Blal Chakhabi¹, Xing Zhao⁴, Xuanfan Zhong⁴, Shengjie Xue⁴, Wuzhong Shen⁴, Ying Tan⁴, Guojian Yu⁴, Guiyun Tu⁴, Hanyang Chen⁴, Amy Sun⁴, Jing Liang⁴, Sharon Song⁴, Jason Xu⁴, Xiaoqiang Yan⁴, Anbing Huang¹ and Qiubai Li⁵, ¹Union Hospital,Tongji Medical College, Huazhong University of Science and Technology, WUHAN, China (People's Republic), ²First People’s Hospital of Jingzhou, Jingzhou, China (People's Republic), ³Zhongnan Hospital, Wuhan University, Wuhan, China (People's Republic), ⁴ITabMed Co., Ltd., Shanghai, China (People's Republic), ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic)

Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…
Abstract Number: 0012 • ACR Convergence 2025
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 or B-cell maturation antigen (BCMA) have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 1683 • ACR Convergence 2025
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
Pierre-Marie Duret¹, Pascal Schneider², Ludivine Robin³, Marine Vierling⁴, Nicolas Meyer⁵, Valerie Devauchelle⁶, Divi Cornec⁷, Alain SARAUX⁸, Jean Sibilia⁹, Raphaele Seror¹⁰, Yann Nguyen¹¹, Gaetane Nocturne¹², Laurent Mauvieux¹³, Laurent Miguet¹⁴, Xavier Mariette¹⁵ and Jacques-eric GOTTENBERG¹⁶, ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²Université de Lausanne,Département de biochimie, Lausanne, Switzerland, ³Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁴Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ⁵Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ⁶UBO, Brest, France, ⁷LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ¹⁰Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹¹Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹²University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ¹³Strasbourg University Hospital, Laboratory hematology, Strasbourg, France,CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁴Strasbourg University Hospital, Laboratory hematology, Strasbourg, France, CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁵Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁶Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 1666 • ACR Convergence 2025
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
John Stone¹, Mollie Carruthers², Alireza Meysami³, Matthew Charles Baker⁴, Daniela Ghetie⁵, Lindsay Lally⁶, Fernando Martinez-Valle⁷, Lorenzo Dagna⁸, nicolas schleinitz⁹, Jeea Choi¹⁰, Leda Mannent¹¹ and Owen Hagino¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Henry Ford Health, Detroit, MI, ⁴Stanford University, Menlo Park, CA, ⁵Oregon Health and Science University, Portland, OR, ⁶Hospital for Special Surgery, NEW YORK, NY, ⁷Vall d’Hebron Hospital, Barcelona, Spain, ⁸IIRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Sanofi, Morristown, NJ, ¹¹Sanofi, Gentilly, France
Background/Purpose: IgG4-RD is a progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is a reversible, orally available inhibitor of Bruton's tyrosine kinase (BTKi). Here,…
Abstract Number: 0946 • ACR Convergence 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Juan Liang¹ and Ting Wang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].